Anti-Human PD-1 Reference Antibody (Cetrelimab, RUO) (HS870046)

Name: Anti-Human PD-1 Reference Antibody (Cetrelimab, RUO)
Brand: abinScience
SKU: HS870046
Price: 176 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HS870046
説明	Cetrelimab (HS870046) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性	Human
アプリケーション	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	IgG4-kappa
ターゲット	CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1
エンドトキシンレベル	< 10 EU/mg
純度	>95% as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	Q15116
形態	Liquid
保存バッファー	0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	JNJ-63723283, 2050478-92-5
背景	Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo). 1. Fife, BT. et al. (2011) Annals of the New York Academy of Sciences 1217, 45-59. PMID: 21276005 2. Bardhan, K. et al. (2019) Scientific reports 9, 17252. PMID: 31754127 3. Patsoukis, N. et al. (2020) Communications biology 3, 128. PMID: 32184441 4. Xiao, X. et al. (2023) Nature communications 14, 2859. PMID: 37208329 5. Zak, KM. et al. (2015) Structure (London, England : 1993) 23, 2341-2348. PMID: 26602187
注意事項	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4) (HP298207) Human IgG4 (S228P) Recombinant Isotype Control Antibody (HyHEL-10) (HP298307) Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107)